Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Athira Pharma Inc.
Headquarters: Seattle, WA, United States of America
Website: http://www.athira.com/
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Mark J. Litton, PhD, MBA
Number Of Employees: 26
Enterprise Value: $-27,481,271
PE Ratio: -0.13
Exchange/Ticker 1: NASDAQ:ATHA
Exchange/Ticker 2: N/A
Latest Market Cap: $12,415,500
BioCentury | Feb 25, 2025
Management Tracks
After leaving FDA, Cavazzoni joins Pfizer as CMO
Plus: CFO hires at Nuclera, Crinetics, Terns and updates from Xeris, Inhibikase and Climb Bio
BioCentury | Nov 19, 2024
Product Development
An understudied dementia soon to get a pair of Phase II readouts
CervoMed and Cognition Therapeutics testing different therapeutic hypotheses in dementia with Lewy bodies
BioCentury | Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
BioCentury | Apr 16, 2024
Management Tracks
Viatris hires Corinne Le Goff as commercial head
Plus: Exact, Obsidian name new CFOs and updates from Applied, Faron, Athira and more
BioCentury | May 23, 2023
Management Tracks
Coelho succeeds Lankry as Gamida CFO
Plus: Sullivan becomes chief strategy officer at BioAge, and updates from Athira, Ambrx and FNIH
BioCentury | Feb 1, 2023
Management Tracks
Okuzawa made president, COO of Daiichi
Plus: new commercial head at Karuna, and updates from Casma, CBER, Optinose, Rally Bio and more
BioCentury | Dec 10, 2022
Discovery & Translation
Blocking FXR for COVID-19; plus Athira’s small molecule for ALS and more
BioCentury’s roundup of translational news
BioCentury | Jun 23, 2022
Product Development
June 22 Quick Takes: Athira sags after Alzheimer’s readout
Plus Athira sags after Alzheimer’s readout, and updates from Merck, Vibe Bio and more
BioCentury | Oct 26, 2021
Management Tracks
Immunomedics vet Itri takes CMO post at
Plus Mersana, Athira, Aprecia and more
BioCentury | Jun 14, 2021
Management Tracks
J&J’s Burton named Moderna CMO; plus Editas, Athira, Yumanity and more
Paul Burton will become CMO at Moderna Inc. (NASDAQ:MRNA) on July 6, succeeding Tal Zaks. Burton is a 16-year veteran of Johnson & Johnson (NYSE:JNJ), most recently serving as chief global medical
Items per page:
1 - 10 of 18